Table 3.
Multivariate analysis related to overall and disease-free survival rates in: (A) 339 patients undergoing radical resection. (B) Approximately 138 patients selected by propensity-score matched analysis by using the 1:2 nearest neighbor technique with a small caliper of 0.15. Cox’s proportional-hazards model.
| A | |||||
|---|---|---|---|---|---|
| Overall Survival | |||||
| Coefficient | Standard Error | Hazard Ratio | 95% CI a Hazard Ratio |
p Value | |
| Age (years) | 1.0349 | 0.2857 | 2.81 | 1.61–4.91 | 0.0003 |
| Serum CEA Levels | 0.9318 | 0.2647 | 2.53 | 1.51–4.25 | 0.0004 |
| Performance Status | 0.5203 | 0.2127 | 1.68 | 1.11–2.54 | 0.01 |
| NPS b | 0.5136 | 0.2069 | 1.67 | 1.11–2.50 | 0.01 |
| pT Stage | 0.1050 | 0.1798 | 1.11 | 0.78–1.57 | 0.55 |
| pN Stage | 0.0920 | 0.0169 | 1.09 | 1.06–1.13 | 0.0001 |
| pM Stage | 0.0351 | 0.0299 | 1.03 | 0.97–1.09 | 0.24 |
| Postoperative Complications | 1.0105 | 0.3331 | 2.74 | 1.43–5.25 | 0.002 |
| Microsatellite Status | 0.3322 | 0.3237 | 1.39 | 0.74–2.62 | 0.30 |
| Disease-Free Survival | |||||
| Coefficient | Standard Error | Hazard Ratio |
95% CI a
Hazard Ratio |
p Value | |
| Serum CEA Levels | 0.7871 | 0.2898 | 2.19 | 1.24–3.86 | 0.006 |
| NPS b | 0.2786 | 0.2271 | 1.32 | 0.84–2.05 | 0.21 |
| pT Stage | 0.6840 | 0.2386 | 1.98 | 1.24–3.15 | 0.004 |
| pN Stage | 0.0647 | 0.0212 | 1.06 | 1.02–1.11 | 0.002 |
| pM Stage | 0.0809 | 0.0303 | 1.08 | 1.02–1.15 | 0.007 |
| Adjuvant Chemotherapy | 0.3646 | 0.4156 | 1.43 | 0.64–3.23 | 0.38 |
| Microsatellite Status | 0.6403 | 0.3461 | 1.89 | 0.96–3.72 | 0.06 |
| B | |||||
| Overall Survival | |||||
| Coefficient | Standard Error | Hazard Ratio |
95% CI a
Hazard Ratio |
p Value | |
| Age (years) | 0.8943 | 0.4485 | 2.44 | 1.01–5.86 | 0.04 |
| Serum CEA Levels | 0.9434 | 0.4884 | 2.56 | 0.99–6.65 | 0.05 |
| Performance Status | 0.7139 | 0.3507 | 2.04 | 1.03–4.04 | 0.04 |
| NPS b | 0.4568 | 0.3472 | 1.57 | 0.80–3.10 | 0.18 |
| pT Stage | 0.2364 | 0.3345 | 1.26 | 0.65–2.43 | 0.47 |
| pN Stage | 0.0999 | 0.0275 | 1.10 | 1.04–1.16 | 0.0003 |
| pM Stage | 0.0157 | 0.0499 | 1.01 | 0.92–1.11 | 0.75 |
| Postoperative Complications | 1.2384 | 0.5650 | 3.45 | 1.14–10.38 | 0.02 |
| Microsatellite Status | 0.6328 | 0.4451 | 1.88 | 0.79–4.48 | 0.15 |
| Disease-Free Survival | |||||
| Coefficient | Standard Error | Hazard Ratio |
95% CI a
Hazard Ratio |
p Value | |
| Serum CEA Levels | 0.4538 | 0.4975 | 1.57 | 0.59–4.15 | 0.36 |
| NPS b | 0.4640 | 0.3955 | 1.59 | 0.73–3.43 | 0.24 |
| pT Stage | 0.8357 | 0.3939 | 2.30 | 1.07–4.97 | 0.03 |
| pN Stage | 0.0505 | 0.5088 | 1.05 | 0.39–2.83 | 0.92 |
| pM Stage | 0.1006 | 0.0477 | 1.10 | 1.00–1.21 | 0.03 |
| Adjuvant Chemotherapy | 0.6785 | 0.7837 | 1.97 | 0.42–9.08 | 0.38 |
| Microsatellite Status | 1.1049 | 0.4771 | 3.01 | 1.19–7.66 | 0.02 |
A multivariate analysis was performed, including variables with significant values on the univariate. Analysis: Postoperative complications were defined as grade II or higher of the Clavien-Dindo classification [27]. a 95% confidence interval. b Naples Prognostic Score (reference n° 21).